Loading quotes...
Forecast
The analysts' average price target is €6.69 (+549.51%). The median is €6.69 (+549.51%).
| Buy |
9 |
| Hold |
3 |
| Sell |
0 |
News Go to news feed
Perspective Therapeutics cooperates with Merck on combination study of [212Pb]PSV359 and Keytruda
Perspective Therapeutics and Merck are conducting a clinical collaboration to evaluate the combination of the alpha‑particle therapy [212Pb]PSV359 and Keytruda (pembrolizumab). The addition is being made in the ongoing Phase‑1/2a trial in patients with FAP‑α‑expressing non‑small cell lung cancer and colorectal cancer; Perspective is the sponsor and Merck is providing pembrolizumab at no cost. The primary objective of the dose‑finding phase is to assess safety and tolerability to establish the recommended Phase‑2 dose; PSV359 is designed to deliver 212Pb selectively to FAP‑α‑positive tumor areas. » More on de.investing.com
Financials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 70.97k | 71.15% |
| Gross profit | 70.97k | 118.88% |
| Net profit | -23.47m | 28.76% |
| EBITDA | -22.41m | 24.90% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €117.18m |
Number of shares | 114.15m |
52-week high/low | €5.50 - €0.95 |
| Dividends | No |
Beta | 1.85 |
P/E ratio | -0.74 |
PEG ratio | 0.04 |
P/B ratio | 0.26 |
P/S ratio | 358.67 |
Company profile
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
| Name | Perspective Therapeutics |
| CEO | Johan Spoor |
| Headquarters | Seattle,
wa USA |
| Website | |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| IPO | 10/11/2005 |
| Employees | 165 |
